TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32859978
Drug: DEGs associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEGs associated with two-component system and pyruvate metabolism
Study: 34355328
Drug: High pollution
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pollution area (PM10: 121.44±43.49 μg/m3, PM2.5: 84.18±31.32 μg/m3)
Study: 34355328
Drug: Moderate pollution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate pollution area (PM10: 89.7±37.34 μg/m3, PM2.5: 58±23.94 μg/m3)
Study: 34355328
Drug: Low pollution
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pollution area (PM10: 59.14±25.24 μg/m3, PM2.5: 38.97±16.87 μg/m3)
Study: 34522871
Drug: L-arginine 1.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 1.66 g twice a day
Study: 35606250
Drug: Nutraceutical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical preparation containing 3.75mg of monacolin K, 515mg of berberine and 50mg of coenzyme Q10 per tablet (Lipok®)
Study: 32537828
Drug: MG impairment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG impairment index
Study: 33177727
Drug: Natural delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural delivery without analgesic measures
Study: 33917922
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (APT)
Study: 34850238
Drug: digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: digital cognitive behavior therapy for insomnia (dCBT‐I)
Study: 36495861
Drug: Genomics-guided therapies,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomics-guided therapies, standardized system for determining actionability of genomic alterations
Study: 34814896
Drug: High Tone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Tone Power Therapy
Study: 34814896
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without High Tone Power Therapy)
Study: 36335376
Drug: Proactive Outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive Outreach with Medication Opt‐out for Tobacco Treatment Engagement (PrOMOTE)
Study: 35802618
Drug: Pre-operative hypnosis
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative hypnosis session and post-operative web-based Acceptance and Commitment Therapy (ACT)
Study: 35802618
Drug: Pre-operative one-session
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative one-session mindfulness through an audio file and post-operative treatment as usual (TAU)
Study: 35358441
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus rituximab (375 mg/m2 on days 3, 10, 17, and 24)
Study: 32573396
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bright light therapy and fluoxetine
Study: 33907251
Drug: Chloroquine 450
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 450 mg BID on day 1 and 450 mg once daily from days 2 to 5 or Hydroxychloroquine 400 mg BID on day 1 and 400 mg once daily from days 2 to 5 (combined with standard care)
Study: 33743063
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of 20-mg dexamethasone (Group B)
Study: 33743063
Drug: Two perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two perioperative doses of 10-mg dexamethasone (Group C)
Study: 33610726
Drug: French maritime
Approvals — FDA: no, EMA: no, PMDA: no
Description: French maritime pine bark extract (PBE) supplementation (50mg, two capsules/day for eight weeks)
Study: 35570989
Drug: Dapagliflozin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin treatment
Study: 33010148
Drug: No dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dapagliflozin treatment (Control)
Study: 32106527
Drug: Liquid PEA
Normalized name: BOOST BREEZE LIQUID PEACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid PEA (167.5 mg Levagen+ with 832.5 mg maltodextrin)
Study: 32106527
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (1 g maltodextrin)
Study: 34775865
Drug: 1% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% glucose isotonic electrolyte solution
Study: 33350447
Drug: Rosuvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin therapy for 48 weeks
Study: 32725758
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation (BA) treatment
Study: 32624569
Drug: 150mg L-DOPA
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg L-DOPA
Study: 38245818
Drug: Etrasimod 2
Normalized name: etrasimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod 2 mg
Study: 32344455
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily for one week
Study: 32962936
Drug: Sugammadex, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex, 4 mg/kg
Study: 32877651
Drug: Trimetazidine 35
Normalized name: trimetazidine 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35 mg modified-release twice daily
Study: 33761688
Drug: Qiming granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiming granule combined with laser treatment
Study: 33761688
Drug: Simple laser
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple laser treatment
Study: 35259535
Drug: Dupilumab 200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200/300 mg
Study: 34153006
Drug: Intrathecal 2‐chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 2‐chloroprocaine 3% 50 mg with fentanyl 15 µg
Study: 34153006
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.75% 9 mg with fentanyl 15 µg
Study: 34185138
Drug: Optimized dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized dose regimen based on BMI
Study: 34217851
Drug: Long-interval dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-interval dinoprostone (3 mg vaginally 12 hours before OH)
Study: 34217851
Drug: Short-interval dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Short-interval dinoprostone (3 mg vaginally 3 hours before OH)
Study: 33465041
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin level < 3.5 mg/dL
Study: 35050548
Drug: Valsartan oral
Normalized name: valsartan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan oral solution 160 mg
Study: 35050548
Drug: Valsartan suspension
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan suspension formulation
Study: 35984425
Drug: Sitagliptin (DPP-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (DPP-4 inhibitor)
Study: 32971991
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg tablet/day)
Study: 34260297
Drug: NACRT (Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACRT (Neoadjuvant chemoradiotherapy) combined with postoperative adjuvant XELOX chemotherapy
Study: 34260297
Drug: ACT (Postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT (Postoperative adjuvant chemotherapy with XELOX)
Study: 32144924
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine basic treatments)
Study: 35090175
Drug: Carrageenan gel
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan gel
Study: 35133871
Drug: Copanlisib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (60 mg intravenous) once weekly on days 1, 8, and 15 in 28-day cycles until progression or toxicity
Study: 32757247
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ITR treatment)
Study: 32026432
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with rituximab
Study: 32026432
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (observation with serial MRI scans)
Study: 32991492
Drug: Maternal use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal use of beta-blockers during the first trimester of pregnancy
Study: 32389105
Drug: Liberal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal blood glucose control (target 10.0-14.0 mmol/L)
Study: 32389105
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (target 6.0-10.0 mmol/L)
Study: 35173379
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) training for 5 weeks, twice a week, 30 min sessions
Study: 34563227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinician and patient-directed nudges
Study: 34953526
Drug: Ad5-nCoV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-nCoV vaccine (0.5 mL dose of 5 × 10^10 viral particle/mL)
Study: 36888640
Drug: Ad5-nCoV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-nCoV vaccine
Study: 36383249
Drug: Caffeine containing
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine containing multi-ingredient pre-workout supplement (SUPP)
Study: 34036721
Drug: Standard-of-care therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapies (radiotherapy and temozolomide chemotherapy)
Study: 34339267
Drug: SPR206 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR206 (10 mg to 400 mg single doses; 25 mg to 150 mg every 8 hours for 7 days; 100 mg every 8 hours for 14 days)
Study: 34339267
Drug: SPR206 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR206 (100 mg every 8 hours for 14 days)
Study: 34339267
Drug: SPR206 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR206 (various doses)
Study: 34706189
Drug: Sotrovimab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab (500 mg single infusion)
Study: 35133556
Drug: PCIT-ED treatment
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIT-ED treatment (n=94)
Study: 34743631
Drug: Audiovisual lecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audiovisual lecture only (Group L)
Study: 37086245
Drug: Istaroxime (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime (0.5 mg/kg/min)
Study: 37086245
Drug: Istaroxime (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime (1.0 mg/kg/min)
Study: 33235342
Drug: Chronic medication
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic medication with anticoagulants or antihypertensives
Study: 33653271
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (COT) - FiO2 of 1.0, 12 L/min
Study: 34330770
Drug: Intermediate-acting insulin
Normalized name: Intermediate-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-acting insulin isophane for postoperative afternoon glucose ≥140 mg/dl
Study: 34330770
Drug: Short-acting insulin
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting insulin for fasting glucose ≥200 mg/dl (control)
Study: 32337566
Drug: Weekly Osteopathic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Osteopathic Manipulative Treatment (OMT) for 12 consecutive weeks
Study: 32450106
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (5 × 10^10 viral particles)
Study: 32450106
Drug: Middle dose
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dose (1 × 10^11 viral particles)
Study: 32450106
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1.5 × 10^11 viral particles)
Study: 34419006
Drug: Far infrared
Normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far infrared therapy (FIR) applied to the skin above the AVF three times a week for 1 year
Study: 34419006
Drug: Far infrared
Normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far infrared therapy (FIR)
Study: 32788865
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (RSV) therapy
Study: 32741946
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus low-dose dexamethasone therapy
Study: 36014810
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic formulation (LabinicTM)
Study: 38082431
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavioral therapy (CBT)
Study: 34753814
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of salbutamol
Study: 34753814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 mL of nebulized sodium chloride)
Study: 35077215
Drug: Combined ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ultrasound and electrostimulation (CUSECS) with standard wound care treatment twice a week for 8 weeks
Study: 35077215
Drug: Standard wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound care treatment once a week for 8 weeks
Study: 35077215
Drug: Standard wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound care treatment
Study: 36112378
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous antibiotic (cloxacillin 2 g per dose)
Study: 36112378
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous antibiotic (cloxacillin 2 g per dose over 24 hours)
Study: 36112378
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous antibiotic
Study: 36112378
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous antibiotic
Study: 33274674
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral feeding
Study: 34959801
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day DHA
Study: 34959801
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day DHA
Study: 35259681
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) control
Study: 34570315
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) adherence intervention
Study: 34570315
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) adherence during lockdown
Study: 35654318
Drug: Losartan (AT1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (AT1R antagonist), single dose
Study: 33784411
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220µg)
Study: 34255874
Drug: BiV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiV therapy
Study: 34491513
Drug: MD (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD (220 mg/m2)
Study: 34491513
Drug: LD (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD (180 mg/m2)
Study: 34491513
Drug: SD (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD (260 mg/m2)
Study: 34798892
Drug: Cranberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry supplementation (144 mg capsule)
Study: 32250330
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (T) therapy
Study: 35728921
Drug: Azithromycin 250-mg
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250-mg tablet manufactured at Pfizer Dalian (China)
Study: 35728921
Drug: Azithromycin 250-mg
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250-mg tablet manufactured at Pfizer Barceloneta (United States)
Study: 32903168
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon angioplasty
Study: 32157686
Drug: Group education
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group education and medical nutrition therapy (MNT) sessions provided within 1-2 weeks of GDM diagnosis.
Study: 35260388
Drug: Biomarker-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided therapy withdrawal (based on S100A12 and hsCRP levels)
Study: 35260388
Drug: Continuing therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing therapy due to elevated S100A12/hsCRP levels
Study: 35260388
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (BiKeR registry, therapy withdrawal without biomarker-based stratification)
Study: 35260388
Drug: Biomarker-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided therapy withdrawal
Study: 35921872
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg in a 24/4‐day regimen
Study: 35320161
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus over 10 min, followed by 1.5 mg/kg/h infusion for 24 hours)
Study: 35320161
Drug: Saline (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo administered at the same rate as lidocaine)
Study: 35787943
Drug: Tegoprazan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (50 mg tablet, once daily) and Naproxen (500 mg tablet, twice daily)
Study: 35787943
Drug: Tegoprazan and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan and Aceclofenac (100 mg tablet, twice daily)
Study: 35787943
Drug: Tegoprazan and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan and Celecoxib (200 mg capsule, twice daily)
Study: 34187840
Drug: Fast fluid
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast fluid infusion (0.90% saline)
Study: 34187840
Drug: Fast fluid
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast fluid infusion
Study: 34187840
Drug: Slow fluid
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow fluid infusion
Study: 36012011
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (ST) twice a week at 75% intensity of one‐repetition maximum for 10 weeks during winter
Study: 35645037
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg cefuroxime sodium plus 500 mg intravenous azithromycin (experimental group)
Study: 35645037
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg cefuroxime sodium plus placebo (placebo group)
Study: 33259240
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A (BTX‐A) injection
Study: 35439645
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no estrogen therapy)
Study: 33525419
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic Weissella cibaria CMU
Study: 34684621
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g MSM daily for 16 weeks
Study: 36321379
Drug: nCT (chemotherapy)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCT (chemotherapy)
Study: 32908007
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Roseomonas mucosa
Study: 35987213
Drug: vehicle glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle glucose or no supplement
Study: 33872583
Drug: Choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline bitartrate supplements (n = 20)
Study: 33872583
Drug: Hardboiled eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hardboiled eggs + choline bitartrate supplements (n = 16)
Study: 33872583
Drug: Egg whites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg whites + choline bitartrate supplements (n = 18)
Study: 33872583
Drug: Phosphatidylcholine supplements
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine supplements (n = 10)